Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | PTPRC | P08575 | 1/20 | 0.54 |
| ▸ | PTPRF | P10586 | 1/20 | 0.54 |
| ▸ | CDC25B | P30305 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497795 | 1.00 | EGFR (0.56) | EGFRTSHRPTPN1PTPRCPTPRF | |
| SCHEMBL29788171 | 0.85 | EGFR (0.49) | EGFRTSHRPTPN1PTPRCPTPRF | |
| SCHEMBL2038076 | 0.85 | EGFR (0.49) | EGFRTSHRPTPN1PTPRCPTPRF | |
| SCHEMBL27708108 | 0.84 | EGFR (0.71) | EGFRTSHRPTPN1PTPRCPTPRF | |
| SCHEMBL28581732 | 0.83 | KDM4E (0.62) | EGFRALDH1A1HSD17B10CA1CA2 | |
| SCHEMBL13232062 | 0.82 | EGFR (0.64) | EGFRTSHRPTPN1PTPRCPTPRF | |
| SCHEMBL396896 | 0.82 | CA12 (0.54) | TSHRALDH1A1HSD17B10CFTRCA1 | |
| SCHEMBL5654036 | 0.82 | CYP1A2 (0.60) | EGFRTSHRPTPN1ALDH1A1HSD17B10 | |
| SCHEMBL16712674 | 0.81 | EGFR (0.63) | EGFRPTPN1ALDH1A1HSD17B10CA1 | |
| SCHEMBL2035147 | 0.81 | EGFR (0.71) | EGFRTSHRPTPN1PTPRCPTPRF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129102-B1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | US HEALTH (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2021068950-A1 | AMIDE COMPOUND AND MEDICAL USE THEREOF AS STING INHIBITOR | 中国药科大学 | 2021-04-15 | — | — | WO | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10738047-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2020-08-11 | — | — | US | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190048001-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | THE US SECRETARY DEPARTMENT OF HEALTH (US) | 2019-02-14 | — | — | US | disclosed |
| US-10131659-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-20 | — | — | US | disclosed |
| EP-3216787-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| US-4201707-A | Methine dyestuffs containing a phenyl azo group | BAYER AKTIENGESELLSCHAFT (DE) | 1980-05-06 | — | — | US | disclosed |
| US-4138570-A | METHINE DYE | BAYER AKTIENGESELLSCHAFT (DE) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | EGFR 1357/4885TSHR 2753/4885PTPN1 4080/4885 |
| US-20190048001-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | NOX5, CYBB, NOX1 | EGFR 4573/4885TSHR 3202/4885PTPN1 897/4885 |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | EGFR 1357/4885TSHR 2753/4885PTPN1 4080/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | EGFR 1357/4885TSHR 2753/4885PTPN1 4080/4885 |
| US-10131659-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | NOX5, CYBB, NOX1 | EGFR 4573/4885TSHR 3202/4885PTPN1 897/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | EGFR 1357/4885TSHR 2753/4885PTPN1 4080/4885 |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | EGFR 1357/4885TSHR 2753/4885PTPN1 4080/4885 |
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | EGFR 855/4885TSHR 380/4885PTPN1 3434/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | EGFR 779/4885TSHR 2802/4885PTPN1 4056/4885 |
| US-10738047-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | NOX5, CYBB, NOX1 | EGFR 4573/4885TSHR 3202/4885PTPN1 897/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | EGFR 1576/4885TSHR 2315/4885PTPN1 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.